Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Posted by on Jun 28, 2020 in Melanoma | 0 comments

In a nutshell The study monitored the occurrence of possible immune-related side effects (irSEs) in patients with advanced melanoma under single and combination therapy of ipilimumab (I; Yervoy), nivolumab (N; Opdivo), and pembrolizumab (P; Keytruda). The authors found that combination therapy increases the frequency of irSEs. Some background...

Read More

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...

Read More

S1-based chemotherapy improves the outcomes of patients with advanced colorectal cancer

S1-based chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jun 25, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of two different chemotherapies in the treatment of advanced colorectal cancer (CRC). Researchers suggested that S1-based chemotherapy is a good option for the treatment of these patients. Some background CRC is one of the most common cancers worldwide. The standard treatment is surgery...

Read More

Can specialized imaging techniques improve how chemo-radiotherapy is administered in locally advanced non-small cell lung cancer?

Posted by on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients.  Some background NSCLC accounts for...

Read More

Do biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?

Posted by on Apr 7, 2020 in Lung cancer | 0 comments

In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...

Read More

Adjuvant chemotherapy improves survival of patients with locally advanced rectal cancer

Posted by on Mar 20, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the role and optimal dose and duration of adjuvant (after surgery) chemotherapy (AC) in patients with locally advanced rectal cancer. Researchers suggested that this treatment was associated with improved survival in these patients. Some background Colorectal cancer is one of the most common cancers worldwide....

Read More

Ipilimumab vs high dose interferon for high risk melanoma

Posted by on Feb 15, 2020 in Melanoma | 0 comments

In a nutshell This study wanted to find out which was the better treatment for advanced melanoma that has been surgically treated, ipilimumab (Yervoy) or high dose interferon alfa (HDI). The study found that low dose ipilimumab resulted in better overall survival than HDI and high dose ipilimumab, but all of the treatments had...

Read More

Are abdominal infections a prognostic factor for recurrence after colorectal cancer surgery?

Posted by on Jan 26, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated whether tummy infections (TIs) after surgery are associated with colorectal cancer outcomes. Researchers suggested that TIs might be associated with a shorter time until recurrence. Some background Colorectal cancer is a common cancer in the US affecting more than 145,000 people every year. Surgery is...

Read More

Durvalumab after chemoradiotherapy for non-small cell lung cancer: analysis from the patients’ perspective

Posted by on Dec 23, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated the patient-reported outcomes after treatment with durvalumab (Imfinzi) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. This study concluded that durvalumab did not affect the quality of life of these patients. Some background NSCLC is the most common form of lung cancer...

Read More

Complete mesocolic excision reduces the risk of recurrence in patients with colon cancer

Posted by on Dec 17, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effects of complete mesocolic excision (CME) in patients with right-side colon cancer. Researchers suggested that CME reduces the risk of recurrences (when cancer comes back) in these patients. Some background Colorectal cancer is one of the most common cancers worldwide. The standard treatment is surgery and...

Read More